therapeutics

Lifespan Vision Ventures Leads Violet Therapeutics’ $4.75M Seed Extension Financing

NORWALK, Conn., May 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human…

2 hours ago

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026

May 17, 2026 16:00 ET  | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,…

18 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian…

2 days ago

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage…

3 days ago

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome…

5 days ago

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events…

6 days ago

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

May 08, 2026 20:45 ET  | Source: Amplia Therapuetics Limited Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia…

1 week ago

Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA

LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport…

3 weeks ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

April 26, 2026 12:00 ET  | Source: Oruka Therapeutics, Inc. MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka…

3 weeks ago

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company…

3 weeks ago